AxoGen, Inc. (NASDAQ: AXGN) is a Healthcare company (Medical - Devices) with a market capitalization of $3.3B. The Maz Rating grades it against the other companies in its sector.
AxoGen, Inc.'s current Maz Rating and its five factor grades are for members: log in to see them.
At $55.37, AxoGen, Inc. trades at 12.5x sales and 6.2x book value. Over the last twelve months it generated about $265M of revenue and a net loss of $39M. It runs a gross margin of 74.2%, an operating margin of -5.2% and a net margin of -12.0%. It shows return on equity of -11.3%, return on invested capital of -2.7% and a free cash flow yield of 0.5%. On the balance sheet: a debt-to-equity ratio of 0.04 and a current ratio of 12.02. Over the past 52 weeks the share price ranged from $23.00 to $59.72, with a beta of 1.15.
AxoGen, Inc. does not currently pay a dividend.
22 Wall Street analyst ratings cover the stock: 19 Buy and 3 Hold, for a Buy consensus. This is the sell side's view, separate from the Maz Rating.
AxoGen, Inc., along with its subsidiaries, specializes in creating and distributing medical devices for the surgical repair of injured or severed peripheral nerves. Their comprehensive product portfolio offers several innovative solutions. The Avance Nerve Graft is a ready-to-use, biologically active human nerve allograft designed to bridge gaps in severed nerves. This avoids the need for a second surgical site for tissue donation, thereby eliminating associated complications. For facilitating the gentle reconnection of severed peripheral nerves, the company offers the AxoGuard Nerve Connector, an extracellular matrix (ECM) derived from porcine submucosa. This same porcine submucosa ECM forms the basis of the AxoGuard Nerve Protector, which is utilized to encase and safeguard damaged peripheral nerves, supporting their reconstruction and preventing unwanted adhesions from surrounding soft tissues. Another ECM product, the AxoGuard Nerve Cap, isolates the nerve end from its environment to help mitigate the formation of painful neuromas. Furthermore, AxoGen provides the Avive Soft Tissue Membrane, a processed human umbilical cord membrane that functions as an absorbable covering for soft tissues, used to separate tissues within the surgical area. An additional tool available is the AxoTouch two-point discriminator, used for evaluating the density of nerve innervation on the skin's surface. These products are supplied to hospitals, surgery centers, and military medical facilities, catering to plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen's market reach extends across the United States, Canada, Germany, the United Kingdom, other European nations, South Korea, and internationally. The company's main operations are situated in Alachua, Florida.
Figures are trailing twelve months unless stated. The Maz Rating and Maz Dividend Score rank a company against its own sector; they are not price targets or recommendations.
It depends on the standard you follow. As of September 2026, AxoGen, Inc. (AXGN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
| Standard | Ratios (value / limit) | Result |
|---|---|---|
| AAOIFI | Debt / Mkt Cap (36m) 0.00% / 30% · (Cash+Inv) / Mkt Cap (36m) 14.4% / 30% · Interest income / Revenue 1.89% / 5% | Pass |
| S&P Global | Debt / Mkt Cap (36m) 0.00% / 33% · (Cash+ST Inv) / Mkt Cap (36m) 14.4% / 33% · Receivables / Mkt Cap (36m) 1.40% / 49% · Interest income / Revenue 1.89% / 5% | Pass |
| Dow Jones | Debt / Mkt Cap (24m) 0.00% / 33.33% · (Cash+ST Inv) / Mkt Cap (24m) 14.4% / 33.33% · Receivables / Mkt Cap (24m) 1.40% / 33.33% · Interest income / Revenue 1.89% / 5% | Pass |
| MSCI | Debt / Avg Assets (4Q) 6.22% / 33.33% · (Cash+ST Inv) / Avg Assets (4Q) 41.0% / 33.33% · Receivables / Avg Assets (4Q) 8.97% / 33.33% · Interest income / Revenue 1.89% / 5% | Fail |
| FTSE | Debt / Total Assets 0.00% / 33.33% · (Cash+ST Inv) / Total Assets 63.2% / 33.33% · (Cash+Recv) / Total Assets 69.4% / 33.33% · Interest income / Revenue 1.89% / 5% | Fail |
It depends on the standard you follow. As of September 2026, AxoGen, Inc. (AXGN) passes 3 of 5 published Shariah screening standards checked by Maz Vantage: it passes AAOIFI, S&P Global and Dow Jones, and fails MSCI and FTSE.
Yes. AxoGen, Inc. is within every AAOIFI limit: debt and interest-bearing cash and investments under 30% of its 36-month average market cap, and interest income under 5% of revenue.
About 1.89% of each dividend: AxoGen, Inc.'s interest income as a share of its revenue. Give that share to charity; the dividend purification calculator works it out per holding.
The screen is rerun on each quarterly report; the figures here are from the balance sheet dated September 30, 2026 (Q3 2026). A status can change from one quarter to the next as debt, cash and market value move.
See also the list of halal stocks, halal healthcare stocks, the halal stock screener, the dividend purification calculator and the zakat calculator.
A mechanical screen of published financial ratios and the company's line of business, not a religious ruling. It does not test every revenue stream; check with a scholar you trust.